Additional value of integrated F-choline PET/4D contrast-enhanced CT in the localization of hyperfunctioning parathyroid glands and correlation with molecular profile.

F Paparo, L Giovanella, M Cabria, L Ceriani, A Arlandini, U Catrambone, G Ferrarazzo, G Paone, M Lanata, P Del Monte, Arnoldo Piccardo, G Treglia, G Bottoni, Anna Crescenzi, L Bacigalupo, L Foppiani, M Puntoni, M Rutigliani, P Trimboli

Journal: European journal of nuclear medicine and molecular imaging 2019;46(3):766-775

PMID: 30219964

Abstract

PURPOSE

The localization of hyperfunctioning parathyroid gland(s) (HPTG) in patients with primary hyperparathyroidism (PHPT) with negative or inconclusive first-line imaging is a significant challenge. This study aimed to evaluate the role of integrated F-choline PET/4D contrast-enhanced computed tomography (4DCeCT) in these patients, compare its detection rate and sensitivity with those of F-choline PET/CT and (4DCeCT), and analyse the association between choline metabolism and morphological, biochemical and molecular parameters of HPTG.

METHODS

We prospectively enrolled 44 PHPT patients with negative or inconclusive first-line imaging. F-Choline PET/CT and 4DCeCT were performed at the same time, and integrated F-choline PET/4DCeCT images were obtained after coregistration. Experienced physicians examined the images. The SUVratio and degree of contrast enhancement were recorded for each positive finding. Histopathology, laboratory and multidisciplinary follow-up were used as the standard of reference. Both the detection rates and sensitivities of the three imaging modalities were calculated retrospectively. Immunohistochemistry was performed to evaluate the molecular profile of HPTGs.

RESULTS

F-Choline PET/4DCeCT was positive in 32 of 44 patients with PHPT (detection rate 72.7%), and 31 of 31 surgically treated patients (sensitivity 100%). These results were significantly (p < 0.05) better than those of F-choline PET/CT (56.8% and 80%, respectively) and those of 4DCeCT (54.5 and 74%, respectively). A significant correlation between SUV and calcium level was found. In a multivariate analysis, only calcium level was significantly associated with F-choline PET/4DCeCT findings. SUVratio and Ki67 expression were significantly correlated.

CONCLUSION

Integrated F-choline PET/4DCeCT should be considered as an effective tool to detect PHPT in patients with negative or inconclusive first-line imaging. Choline metabolism is correlated with both calcium level and Ki67 expression in HPTG.

Address: Department of Nuclear Medicine, Galliera Hospital, Mura delle Cappuccine 14, 16128, Genoa, Italy. [email protected].; Department of Nuclear Medicine and PET/CT Centre, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland. [email protected].; Department of Nuclear Medicine and PET/CT Centre, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.; Department of Histopathology, Galliera Hospital, Mura delle Cappuccine 14, 16128, Genoa, Italy.; Clinical Trial Unit, Office of the Scientific Director, Galliera Hospital, Mura delle Cappuccine 14, 16128, Genoa, Italy.; Department of Internal Medicine, Galliera Hospital, Mura delle Cappuccine 14, 16128, Genoa, Italy.; Department of Radiology, Galliera Hospital, Mura delle Cappuccine 14, 16128, Genoa, Italy.; Pathology Unit, University Hospital Campus Bio Medico, Rome, Italy.; Department of Nuclear Medicine, Galliera Hospital, Mura delle Cappuccine 14, 16128, Genoa, Italy.; Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, Lausanne, Switzerland.; Department of Endocrinology, Galliera Hospital, Mura delle Cappuccine 14, 16128, Genoa, Italy.; Department of Surgery, Galliera Hospital, Mura delle Cappuccine 14, 16128, Genoa, Italy.

Link outs

Free resources

Other Literature Sources:

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.